Time To Spare? US FDA “Opioid-Sparing” Guidance May Take Longer Than Expected
In August, it sounded like FDA was almost ready to issue guidance on “opioid-sparing” claims for acute pain treatments. After a November advisory committee meeting, that doesn’t seem to be the case.